Johnson & Johnson
NYSE:JNJ

Watchlist Manager
Johnson & Johnson Logo
Johnson & Johnson
NYSE:JNJ
Watchlist
Price: 157.1 USD 0.28% Market Closed
Market Cap: 378B USD

Net Margin
Johnson & Johnson

24.4%
Current
28%
Average
5.1%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
24.4%
=
Net Income
21.8B
/
Revenue
89.3B

Net Margin Across Competitors

Country Company Market Cap Net
Margin
US
Johnson & Johnson
NYSE:JNJ
377.9B USD
24%
US
Eli Lilly and Co
NYSE:LLY
776.5B USD
23%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
-4%
DK
Novo Nordisk A/S
CSE:NOVO B
2.3T DKK
35%
CH
Roche Holding AG
SIX:ROG
210.7B CHF
14%
CH
Novartis AG
SIX:NOVN
188.9B CHF
24%
UK
AstraZeneca PLC
LSE:AZN
169.4B GBP
14%
US
Merck & Co Inc
NYSE:MRK
203.6B USD
27%
IE
Endo International PLC
LSE:0Y5F
163.5B USD
-126%
US
Pfizer Inc
NYSE:PFE
139.5B USD
13%
FR
Sanofi SA
PAR:SAN
108.7B EUR
14%

Johnson & Johnson
Glance View

Economic Moat
Wide
Market Cap
377.9B USD
Industry
Pharmaceuticals

Founded in 1886, Johnson & Johnson began its journey with a commitment to revolutionizing healthcare, starting with the sterile surgical dressings it produced to reduce infections in hospitals. Over the decades, this vision expanded into a global healthcare powerhouse, intricate in its operation yet unified in its mission to improve lives. Johnson & Johnson's business model is built on three core segments: pharmaceuticals, medical devices, and consumer health products. Each segment harnesses the synergy of innovation, research, and a deep understanding of customer needs. The pharmaceutical division, one of its most robust, thrives on producing treatments for various medical conditions, including immunology, oncology, and neuroscience. It is in this domain that cutting-edge research and development efforts translate into high-margin therapies, driving substantial portions of the company's revenue. Beyond pharmaceuticals, the medical devices segment forms a pillar of Johnson & Johnson's operations, offering a spectrum of products essential for surgeries, orthopedics, and vision care. These devices are integral for modern healthcare practices, with their premium positioning contributing significantly to the company’s financial health. Meanwhile, Johnson & Johnson's consumer health division addresses everyday wellness needs, with iconic brands like Band-Aid, Tylenol, and Neutrogena. This segment leverages global brand recognition and trust to generate steady, albeit lower-margin, income streams. Together, these segments compose a diversified revenue platform, buffered against sector-specific downturns and positioning Johnson & Johnson as a formidable entity in global healthcare markets.

JNJ Intrinsic Value
162.58 USD
Undervaluation 3%
Intrinsic Value
Price
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
24.4%
=
Net Income
21.8B
/
Revenue
89.3B
What is the Net Margin of Johnson & Johnson?

Based on Johnson & Johnson's most recent financial statements, the company has Net Margin of 24.4%.

Back to Top